Why are Genentech’s cancer researchers concerned about the direction of the company? What led Pfizer to pull its sickle cell drug off global markets? And what cake did Adam make for all his podcast colleagues except Elaine?
We talk about all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jonathan Wosen joins us to discuss the recent setbacks and wins in oncology R&D, including Genentech’s decision to shut down its cancer immunology group, and the global ambitions of Akeso, the Chinese biotech behind Summit Therapeutics’ recent positive results.
Click this link for the original source of this article.
Author: Elaine Chen, Allison DeAngelis, and Adam Feuerstein
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
